Zoledronic acid in the management of metastatic bone disease

Expert Opinion on Biological Therapy

Volumn 6, Issue 12, 2006, Pages 1333-1348

  Santini, Daniele ^a   Fratto, Maria Elisabetta ^a   Vincenzi, Bruno ^a   Galluzzo, Sara ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Bisphosphonates; Clinical activity; Practice in oncology

Indexed keywords

ALENDRONIC ACID; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLORHEXIDINE; CLINDAMYCIN; CLODRONIC ACID; CYCLOPLEGIC AGENT; CYTOSTATIC AGENT; DENOSUMAB; ERYTHROPOIETIN; ETIDRONIC ACID; IBANDRONIC ACID; INCADRONIC ACID; PAMIDRONIC ACID; PARACETAMOL; PENICILLIN G; PLACEBO; RISEDRONIC ACID; STEROID; THALIDOMIDE; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ANEMIA; ARTHRALGIA; BLADDER CANCER; BLURRED VISION; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; CRANIAL NERVE PARALYSIS; DIPLOPIA; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; EPIPHORA; EPISCLERITIS; EYE DISEASE; EYE IRRITATION; EYELID EDEMA; FANCONI RENOTUBULAR SYNDROME; FATIGUE; FEVER; FLU LIKE SYNDROME; HUMAN; HYPERCALCEMIA; HYPERMAGNESEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; IN VIVO STUDY; INJECTION SITE INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY CARCINOMA; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTE; META ANALYSIS; MORBIDITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEPHROTIC SYNDROME; NEPHROTOXICITY; ORBIT DISEASE; OSTEOCLAST; OSTEOLYSIS; OSTEOMYELITIS; PHOTOPHOBIA; PRACTICE GUIDELINE; PROSTATE CANCER; REVIEW; SCLERITIS; SIDE EFFECT; SOLID TUMOR; SYSTEMATIC REVIEW; TUMOR CELL; UVEITIS; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES;

EID: 33845299812     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.12.1333     Document Type: Review

References (125)

1. MERCADANTE S: Malignant bone pain: pathophysiology and treatment. Pain (1997) 69:1-18.
2. COLEMAN RE: Skeletal complications of malignancy. Cancer (1997) 80(Suppl. 8):1588-1594.
3. SHINODA H, ADAMEK G, FELIX R et al.: Structure-activity relationship of various bisphosphonates. Calcif. Tissue Int. (1983) 35:87-99.
4. WIDLER R, JAEGGI KA, GLATT M et al.: Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J. Med. Chem. (2002) 45(17):3721-3738.
5. SCHENK R, EGGLI P, FLEISCH H, ROSINI S: Quantitative morphometric evaluation of the inhibitory activity of new amino-bisphosphonates on bone resorption in the rat. Calcif. Tissue Int. (1986) 38:342-349.
6. SIETSEMA WK, EBETINO FH, SALVAGNO AM, BEVAN JA: Antiresorptive dose-response relationship across three generations of bisphosphonates. Drugs Exp. Clin. Res. (1989) 15:389-396.
7. GREEN JR, MULLER K, JAEGGI KA: Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. (1994) 9:745-751.
8. RACKOFF PJ, SEBBA A: Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis. Treat. Endocrinol. (2005) 4(4):245-251.
9. CRANNEY A, ADACHI JD: Corticosteroid-induced osteoporosis: a guide to optimum management. Treat. Endocrinol. (2002) 1(5):271-279.
10. REID IR, MILLER P, LYLES K et al.: Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. (2005) 353(9):898-908.
11. FLEISCH H: Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcemic and metastatic bone disease. Drugs (1991) 42:919-944.
12. MCCLOSKEY EV, MACLENNAN CM, DRAYSON MT et al.: A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br. J. Haematol. (1998) 100:317-325.
13. HORTOBAGYI GN, THERIAULT RL, PORTER L et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. (1996) 335:1785-1791.
14. ROGERS MJ, BROWN RJ, HODKIN V et al.: Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem. Biophys. Res. Commun. (1996) 224:863-869.
15. ROGERS MJ, JI X, RUSSELL RG et al.: Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem. J. (1994) 303:303-311.
16. VAN BEEK E, PIETERMAN E, COHEN L et al.: Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. (1999) 264:108-111.
17. ZHANG FL, CASEY PJ: Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. (1996) 65:241-269.
18. VAN BEEK E, LOWIK C, VAN DER PLUIJM G, PAPAPOULOS S: The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J. Bone Miner. Res. (1999) 14:722-729.
19. SATO M, GRASSER W: Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J. Bone Miner. Res. (1990) 5:31-40.
20. DE LIBERO G: Sentinel function of broadly reactive human γδ T cells. Immunol. Today (1997) 18:22-26.
21. FISCH P, MALKOVSKY M, KOVATS S et al.: Recognition by human Vγ9/Vδ2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science (1990) 250:1269-1273.
22. BUKOWSKI JF, MORITA CT, TANAKA Y et al.: Vγ9/Vδ2 TCR-dependent recognition of nonpeptide antigens and Daudi cells analyzed by TCR gene transfer. J. Immunol. (1995) 154:998-1006.
23. KUNZMANN V, BAUER E, FEURLE J et al.: Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood (2000) 96:384-392.
24. KUNZMANN V, BAUER E, WILHELM M: γδ cell stimulation by pamidronate. N. Engl. J. Med. (1999) 340:737-738. •• The first in vivo demonstration of association between pamidronate administration and activation of γ/δ T cells.
25. GOBER HJ, KISTOWSKA M, ANGMAN L, JENO P, MORI L, DE LIBERO G: Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. (2003) 197(2):163-168.
26. WILHELM M, KUNZMANN V, ECKSTEIN S et al.: Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood (2003) 102(1):200-206.
27. SANTINI D, VESPASIANI GENTILUCCI U, VINCENZI B et al.: The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann. Oncol. (2003) 14:1468-1476. • A comprehensive review about preclinical and clinical data on the antineoplastic role of bisphosphonates.
28. JOHNSON JR, WILLIAMS G, PAZDUR R: End points and United States Food and Drug Administration approval of oncology drugs. J. Clin. Oncol. (2003) 21:1404-1411.
29. WILLIAMS G, PAZDUR R, TEMPLE R: Assessing tumor-related signs and symptoms to support cancer drug approval. J. Biopharm. Stat. (2004) 14:5-21.
30. MAJOR PP, COOK RJ, CHEN BL et al.: Survival-adjusted cumulative event analysis of skeletal-related events in patients with cancer metastatic to bone in trials of zoledronic acid. Presented at: What is new in bisphosphonates? Seventh workshop on bisphosphonates. From the laboratory to the patient. Davos, Switzerland (24 - 26 March 2004).
31. ANDERSEN PK, GILL RD: Cox's regression model for counting processes: a large sample study. Ann. Stat. (1982) 10:1100-1120.
32. MAJOR P, LORTHOLARY A, HON J et al.: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. (2001) 19:558-567. • Important evidence demonstrating that zoledronic acid is the best therapy for HCM.
33. BODY JJ: Hypercalcemia of malignancy. Semin. Nephrol. (2004) 24(1):48-54.
34. BELCH AR, BERGSAGEL DE, WILSON K et al.: Effect of daily etidronate on the osteolysis of multiple myeloma. J. Clin. Oncol. (1991) 9:1397-1402.
35. DARAGON A, HUMEZ C, MICHOT C et al.: Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Eur. J. Med. (1993) 2:449-452.
36. DJULBEGOVIC B, WHEATLEY K, ROSS J et al.: Bisphosphonates in multiple myeloma. Cochrane Database Syst. Rev. (2002) 3:CD003188.
37. BERENSON JR, ROSEN LS, HOWELL A et al.: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer (2001) 91:1191-1200.
38. ROSEN LS, GORDON D, KAMINSKI M et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. (2001) 7:377-387.
39. ROSEN LS, GORDON D, KAMINSKI M et al.: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer (2003) 98:1735-1744. •• The first randomised trial demonstrating that zoledronic acid is superior to pamidronate in prevention of SREs in patients with bone metastases from multiple myeloma and breast cancer.
40. DIMOPOULOS M, BERENSON J, SHIRINA N, CHEN YM: Survival in patients with multiple myeloma receiving zoledronic acid: Stratification by baseline bone alkaline phosphatase levels. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. (2006) 18S(Suppl.):7505.
41. HILLNER BE, INGLE JN, CHLEBOWSKI RT et al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. (2003) 21(21):4042-4057. •• The most recent ASCO recommendations regarding bisphosphonate therapy in women with breast cancer.
42. COLEMAN RE: Bisphosphonates in breast cancer. Ann. Oncol. (2005) 16(5):687-695.
43. PATERSON AH, POWLES TJ, KANIS JA et al.: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. (1993) 11:59-65.
44. KRISTENSEN B, EJLERTSEN B, GROENVOLD M et al.: Oral clodronate in breast cancer patients with bone metastases: a randomized study. J. Intern. Med. (1999) 246:67-74.
45. TUBIANA-HULIN M, BEUZEBOC P, MAURIAC L et al.: Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull. Cancer (2001) 88:701-707.
46. HORTOBAGYI GN, THERIAULT RL, LIPTON A et al.: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. (1998) 16:2038-2044.
47. THERIAULT RL, LIPTON A, HORTOBAGYI GN et al.: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J. Clin. Oncol. (1999) 17:846-854.
48. LIPTON A, THERIAULT RL, HORTOBAGYI GN et al.: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer (2000) 88:1082-1090.
49. HULTBORN R, GUNDERSEN S, RYDEN S et al.: Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res. (1999) 19:3383-3392.
50. CONTE PF, LATREILLE J, MAURIAC L et al.: Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J. Clin. Oncol. (1996) 14:2552-2559.
51. BODY JJ, DIEL IJ, LICHINITSER MR et al.: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. (2003) 14:1399-1405.
52. BODY JJ, DIEL IJ, LICHINITZER M et al.: Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br. J. Cancer (2004) 90:1133-1137.
53. KOHNO N, AOGI K, MINAMI H et al.: A randomized, double-blind, placebo-controlled Phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer. Proc. Am. Soc. Clin. Oncol. (2004) 23:43.
54. MAJOR PP, COOK RJ, CHEN BL, ZHENG N: Multiple event analysis of zoledronic acid trials in patients with cancer metastatic to bone. Proc. Am. Soc. Clin. Oncol. (2003) 22:762 (Abstract 3062).
55. ROSEN LS, GORDON DH, DUGAN W JR et al.: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer (2004) 100:36-43.
56. CARAGLIA M, SANTINI D, MARRA M, VINCENZI B, TONINI G, BUDILLON A: Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr. Relat. Cancer (2006) 13(1):7-26. • A comprehensive review about the molecular mechanisms of the antineoplastic role of bisphosphonates.
57. CLEMONS MJ, DRANITSARIS G, OOI WS et al.: Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J. Clin. Oncol. (2006) 24(30):4895-4900.
58. GARNERO P, BUCHS N, ZEKRI J, RIZZOLI R, COLEMAN RE, DELMAS PD: Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer (2000) 82:858-864.
59. BROWN JE, NEVILLE-WEBBE H, COLEMAN R: The role of bisphosphonates in breast and prostate cancers. Endocr. Relat. Cancer (2004) 11:207-224
60. SMITH JA: Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J. Urol. (1989) 141:85-87.
61. ELOMAA I, KYLMALA T, TAMMELA T et al.: Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostate cancer. Int. Urol. Nephrol. (1992) 24:159-166.
62. KYLMALA T, TAMMELA TL, LINDHOLM TS, SEPPANEN J: The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann. Chir. Gynaecol. (1994) 83:316-319.
63. KYLMALA T, TAUBE T, TAMMELA TL, RISTELI L, RISTELI J, ELOMA A: Concomitant i.v. and oral clodronate in the relief of bone pain - a double-blind placebo-controlled study in patients with prostate cancer. Br. J. Cancer (1997) 76:939-942.
64. STRANG P, NILSSON S, BRANDSTEDT S et al.: The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res. (1997) 17:4717-4721.
65. ERNST DS, TANNOCK IF, VENNER PM et al.: Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study. Proc. Am. Soc. Clin. Oncol. (2002) 21:705.
66. DEARNALEY D, SYDES MR, MASON MD et al.: A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J. Natl Cancer Inst. (2003) 95:1300-1311.
67. LIPTON A, SMALL E, SAAD F et al.: The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. (2002) 20(Suppl. 2):45-54.
68. SAAD F, GLEASON DM, MURRAY R et al.: Zoledronic acid reduces skeletal complications in patients with hormone-refractory prostate carcinoma metastatic to bone: a randomized, placebo-controlled trial. J. Natl. Cancer Inst. (2002) 94:1458-1468. • One of the first and most persuasive demonstrations of the clinical impact of zoledronic acid in patients with bone metastases from prostate cancer.
69. COLEMAN R, ROSEN L, GLEASON DM et al.: Zoledronic acid has broad long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer, prostate cancer, and other solid tumours. Presented at: What is new in bisphosphonates? Seventh workshop on bisphosphonates. From the laboratory to the patient. Davos, Switzerland (24 - 26 March 2004).
70. SAAD F, GLEASON D, MURRAY R et al.: Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases. Presented at: XIXth Congress of the European Association of Urology. Vienna, Austria (24 - 27 March 2004).
71. SAAD F, GLEASON D, MURRAY R et al.: Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone. J. Urol. (2003) 169:394.
72. WEINFURT KP, LI Y, CASTEL LD et al.: The impact of skeletal related events on health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol. (2002) 13(Suppl. 5):180.
73. ROSEN LS, GORDON D, TCHEKMEDYIAN NS et al.: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer (2004) 100:2613-2621. •• The first clinical evidence on the efficacy of zoledronic acid in patients with different solid tumours.
74. LIPTON A, SEAMAN J, ZHENG M: Long-term efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Presented at: What is new in bisphosphonates? Seventh workshop on bisphosphonates. From the laboratory to the patient. Davos, Switzetland (24 - 26 March 2004).
75. COLEMAN RE: Bisphosphonates: clinical experience. Oncologist (2004) 9(Suppl. 4):14-27. • A thorough review of clinical trials demonstrating bisphosphonate efficacy.
76. BODY JJ, LICHINITSER M, TJULANDIN S et al.: Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: comparative bone turnover marker and safety data. Bone (2006) 38(Suppl. 1):S69.
77. RIVKIN S: Oral ibandronate versus intravenous zoledronic acid for breast cancer patients with skeletal complications: the SWOG trial. Bone (2006) 38(Suppl. 1):S82.
78. BARRETT-LEE P, MURRAY N: Zoledronic acid versus ibandronate comparative evaluation in breast cancer patients with bone metastases: the NCRI ZICE trial. Bone (2006) 38(Suppl. 1):S57.
79. CAMERON D, FALLON M, DIEL I: Ibandronate: its role in metastatic breast cancer. Oncologist (2006) 11(Suppl. 1):27-33.
80. ABRAHAMSEN B, TENG AY: Technology evaluation: denosumab, Amgen. Curr. Opin. Mol. Ther. (2005) 7(6):604-10
81. LIPTON A, ALVARADO C, DE BOER R et al.: Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP). ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. (2006) 24(18S):512.
82. SUAREZ T, FIZAZI K, RAHIM Y et al.: A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. (2006) 24(18S):8562.
83. BERENSON JR, HILLNER BE, KYLE RA et al.: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. (2002) 20:3719-3736.
84. HILLNER BE, INGLE JN, BERENSON JR et al.: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J. Clin. Oncol. (2000) 18:1378-1391.
85. BERENSON JR: Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist (2005) 10:52-62.
86. COSTA L, DEMERS LM, GOUVEIA-OLIVEIRA A et al.: Prospective evaluation of the peptide-bound collagen Type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J. Clin. Oncol. (2002) 20:850-856.
87. BROWN J, COOK R, COLEMAN RE et al.: The role of bone turnover markers in predicting clinical events in metastatic bone disease. Proc. Am. Soc. Clin. Oncol. (2003) 22:738.
88. MAXWELL C, SWIFT R, GOODE M, DOANE L, ROGERS M: Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. Clin. J. Oncol. Nurs. (2003) 7(4):403-408.
89. ZOJER N, KECK AV, PECHERSTORFER M: Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf. (1999) 21:389-406.
90. MUNNS CF, RAUCH F, MIER RJ, GLORIEUX FH: Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone (2004) 35(1):231-234.
91. PECHERSTORFER M, JILCH R, SAUTY A et al.: Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J. Bone Miner. Res. (2000) 15(1):147-154.
92. BANERJEE D, ASIF A, STRIKER L et al.: Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am. J. Kidney Dis. (2003) 41(5):E18.
93. CHANG JT, GREEN L, BEITZ J: Renal failure with the use of zoledronic acid. N. Engl. J. Med. (2003) 349(17):1676-1679.
94. ROSEN LS, GORDON D, TCHEKMEDYIAN S et al.: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial. J. Clin. Oncol. (2003) 21(16):3150-3157.
95. MAZJ S, LICHTMAN SM: Renal dysfunction associated with bisphosphonate use: retrospective analysis of 293 patients with respect to age and other clinical characteristics. Proc. Am. Soc. Clin. Oncol. (2004) 23:735a.
96. GUARNERI V, DONATI S, NICOLINI M, CONTE P: Renal safety of zoledronic acid in patients with bone metastases from breast cancer or other tumors treated with intravenous bisphosphonates for up to ten years. Ann. Oncol. (2004) 15(Suppl. 3):811p.
97. KYLE RA: Update on the treatment of multiple myeloma. Oncologist (2001) 6:119-124.
98. MARKOWITZ GS, FINE PL, STACK JI et al.: Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. (2003) 64(1):281-289.
99. WOO SB, HELLSTEIN JW, KALMAR JR: Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. (2006) 144(10):753-761.
100. MAEREVOET M, MARTIN C, DUCK L: Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. (2005) 353(1):99-102.
101. BAGAN JV, MURILLO J, JIMENEZ Y et al.: Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J. Oral. Pathol. Med. (2005) 34(2):120-123.
102. CARTER GD, GOSS AN: Bisphosphonates and avascular necrosis of the jaws. Austr. Dent. J. (2003) 48(4):268.
103. MARX RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral. Maxillofac. Surg. (2003) 61:1115-1117.
104. SCHUSTER MW, DYMEK JM: Oral cavity avascular bone necrosis-a newly recognized complication of intravenous (iv) bisphosphonate therapy in cancer patients. Blood (2004) 104:4905.
105. RUGGIERO SL, MEHROTRA B, ROSENBERG TJ, ENGROFF SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. (2004) 62(5):527-534.
106. MIGLIORATI CA, SIEGEL MA, ELTING LS: Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. (2006) 7(6):508-514.
107. GREENBERG MS: Intravenous bisphosphonates and osteonecrosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (2004) 98(3):259-260.
108. ESTILO CL, VAN POZNAK CH, WILLIAMS T et al.: Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study. 2004. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol. (2004) 22(14S):8088.
109. MIGLIORATI CA, SCHUBERT MM, PETERSON DE, SENEDA LM: Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer (2005) 104(1):83-93.
110. GREENBERG MS: Intravenous bisphosphonates and osteonecrosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (2004) 98(3):259-260.
111. SIMS EC, ROGERS PB, BESSER GM, PLOWMAN PN: Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia. Clin. Oncol. (R. Coll. Radiol.) (1998) 10(6):407-409.
112. PETER R, MISHRA V, FRASER WD: Severe hypocalcaemia after being given intravenous bisphosphonate. Br. Med. J. (2004) 328(7435):335-336.
113. ROSEN CJ, BROWN S: Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N. Engl. J. Med. (2003) 348(15):1503-504.
114. NGUYEN HV, INGRAM KB, BEILIN J: Profound hypocalcaemia after zoledronic acid treatment. Med. J. Austr. (2005) 182(9):494-495.
115. MISHRA A, WONG L, JONKLAAS J: Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine (2001) 14(2):159-164.
116. DURNIAN JM, OLUJOHUNGBE A, KYLE G: Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy. Eye (2005) 19(2):221-222.
117. FRAUNFELDER FW, FRAUNFELDER FT, JENSVOLD B: Scleritis and other ocular side effects associated with pamidronate disodium. Am. J. Ophthalmol. (2003) 135(2):219-222.
118. DE S, MEYER P, CRISP AJ: Pamidronate and uveitis. Br. J. Rheumatol. (1995) 34(5):479.
119. STEWART GO, STUCKEY BG, WARD LC et al.: Iritis following intravenous pamidronate. Aust. NZ. J. Med. (1996) 26(3):414-415.
120. MACAROL V, FRAUNFELDER FT: Pamidronate disodium and possible ocular adverse drug reactions. Am. J. Ophthalmol. (1994) 118(2):220-224.
121. SUBRAMANIAN PS, KERRISON JB, CALVERT PC, MILLER NR: Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. Arch. Ophthalmol. (2003) 121(9):1335-1336.
122. TANVETYANON T, STIFF PJ: Management of the adverse effects associated with intravenous bisphosphonates. Ann. Oncol. (2006) 17:897-907. • A systematic review regarding side effects due to bisphosphonate therapy.
123. BRUFSKY A: Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin. Oncol. (2006) 33(2 Suppl. 7):S13-S17.
124. LIPTON A: Toward new horizons: the future of bisphosphonate therapy. Oncologist (2004) 9(Suppl. 4):38-47.
125. CLEZARDIN P: The antitumor potential of bisphosphonates. Semin. Oncol. (2002) 29(Suppl. 21):33-42.